Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial

DOI record: { "DOI": "10.1007/s40121-021-00496-6", "ISSN": [ "2193-8229", "2193-6382" ], "URL": "http://dx.doi.org/10.1007/s40121-021-00496-6", "alternative-id": [ "496" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "3 June 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "1 July 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "28 July 2021" } ], "author": [ { "ORCID": "http://orcid.org/0000-0003-2971-5141", "affiliation": [], "authenticated-orcid": false, "family": "Bosaeed", "given": "Mohammad", "sequence": "first" }, { "affiliation": [], "family": "Mahmoud", "given": "Ebrahim", "sequence": "additional" }, { "affiliation": [], "family": "Alharbi", "given": "Ahmad", "sequence": "additional" }, { "affiliation": [], "family": "Altayib", "given": "Hadeel", "sequence": "additional" }, { "affiliation": [], "family": "Albayat", "given": "Hawra", "sequence": "additional" }, { "affiliation": [], "family": "Alharbi", "given": "Faisal", "sequence": "additional" }, { "affiliation": [], "family": "Ghalilah", "given": "Khalid", "sequence": "additional" }, { "affiliation": [], "family": "Al Arfaj", "given": "Abdulmajid", "sequence": "additional" }, { "affiliation": [], "family": "AlJishi", "given": "Jumana", "sequence": "additional" }, { "affiliation": [], "family": "Alarfaj", "given": "Abdullatif", "sequence": "additional" }, { "affiliation": [], "family": "Alqahtani", "given": "Hajar", "sequence": "additional" }, { "affiliation": [], "family": "Almutairi", "given": "Badriah M.", "sequence": "additional" }, { "affiliation": [], "family": "Almaghaslah", "given": "Manar", "sequence": "additional" }, { "affiliation": [], "family": "Alyahya", "given": "Nawaf M.", "sequence": "additional" }, { "affiliation": [], "family": "Bawazir", "given": "Abdullah", "sequence": "additional" }, { "affiliation": [], "family": "AlEisa", "given": "Saud", "sequence": "additional" }, { "affiliation": [], "family": "Alsaedy", "given": "Abdulrahman", "sequence": "additional" }, { "affiliation": [], "family": "Bouchama", "given": "Abderrezak", "sequence": "additional" }, { "affiliation": [], "family": "Alharbi", "given": "Malak", "sequence": "additional" }, { "affiliation": [], "family": "AlShamrani", "given": "Majid", "sequence": "additional" }, { "affiliation": [], "family": "Al Johani", "given": "Sameera", "sequence": "additional" }, { "affiliation": [], "family": "Aljeraisy", "given": "Majed", "sequence": "additional" }, { "affiliation": [], "family": "Alzahrani", "given": "Mohammed", "sequence": "additional" }, { "affiliation": [], "family": "Althaqafi", "given": "Abdulhakeem O.", "sequence": "additional" }, { "affiliation": [], "family": "Almarhabi", "given": "Hassan", "sequence": "additional" }, { "affiliation": [], "family": "Alotaibi", "given": "Athari", "sequence": "additional" }, { "affiliation": [], "family": "Alqahtani", "given": "Nasser", "sequence": "additional" }, { "affiliation": [], "family": "Arabi", "given": "Yaseen M.", "sequence": "additional" }, { "affiliation": [], "family": "Aldibasi", "given": "Omar S.", "sequence": "additional" }, { "affiliation": [], "family": "Alaskar", "given": "Ahmad", "sequence": "additional" } ], "clinical-trial-number": [ { "clinical-trial-number": "nct04392973", "registry": "10.18810/clinical-trials-gov" } ], "container-title": "Infectious Diseases and Therapy", "container-title-short": "Infect Dis Ther", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2021, 8, 10 ] ], "date-time": "2021-08-10T17:07:26Z", "timestamp": 1628615246000 }, "deposited": { "date-parts": [ [ 2023, 1, 7 ] ], "date-time": "2023-01-07T02:05:55Z", "timestamp": 1673057155000 }, "funder": [ { "DOI": "10.13039/501100013302", "award": [ "RC20/174/R" ], "doi-asserted-by": "publisher", "name": "King Abdullah International Medical Research Center" } ], "indexed": { "date-parts": [ [ 2024, 2, 7 ] ], "date-time": "2024-02-07T08:36:27Z", "timestamp": 1707294987655 }, "is-referenced-by-count": 9, "issue": "4", "issued": { "date-parts": [ [ 2021, 7, 28 ] ] }, "journal-issue": { "issue": "4", "published-print": { "date-parts": [ [ 2021, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 7, 28 ] ], "date-time": "2021-07-28T00:00:00Z", "timestamp": 1627430400000 } }, { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 7, 28 ] ], "date-time": "2021-07-28T00:00:00Z", "timestamp": 1627430400000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s40121-021-00496-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s40121-021-00496-6/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s40121-021-00496-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "page": "2291-2307", "prefix": "10.1007", "published": { "date-parts": [ [ 2021, 7, 28 ] ] }, "published-online": { "date-parts": [ [ 2021, 7, 28 ] ] }, "published-print": { "date-parts": [ [ 2021, 12 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "key": "496_CR1", "unstructured": "World Health Organization. Coronavirus Disease (COVID-19) Situation Report. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 15 2021. (Published 15 April 2021)." }, { "DOI": "10.1001/jama.2020.2648", "author": "Z Wu", "doi-asserted-by": "publisher", "first-page": "1239", "issue": "13", "journal-title": "JAMA", "key": "496_CR2", "unstructured": "Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323 (13):1239.", "volume": "323", "year": "2020" }, { "DOI": "10.1001/jamanetworkopen.2020.29058", "author": "N Rosenthal", "doi-asserted-by": "publisher", "first-page": "e2029058", "issue": "12", "journal-title": "JAMA Netw Open.", "key": "496_CR3", "unstructured": "Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19. JAMA Netw Open. 2020;3 (12):e2029058.", "volume": "3", "year": "2020" }, { "DOI": "10.1001/jamainternmed.2020.3596", "author": "S Gupta", "doi-asserted-by": "publisher", "first-page": "1436", "issue": "11", "journal-title": "JAMA Intern Med", "key": "496_CR4", "unstructured": "Gupta S, Hayek SS, Wang W, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180 (11):1436.", "volume": "180", "year": "2020" }, { "DOI": "10.1056/NEJMoa2021436", "author": "P Horby", "doi-asserted-by": "publisher", "first-page": "693", "issue": "8", "journal-title": "N Engl J Med.", "key": "496_CR5", "unstructured": "Horby P, Lim WS, RECOVERY Collaborative Group, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384 (8):693–704.", "volume": "384", "year": "2021" }, { "DOI": "10.1056/NEJMoa2100433", "author": "AC Gordon", "doi-asserted-by": "publisher", "first-page": "1491", "issue": "16", "journal-title": "N Engl J Med.", "key": "496_CR6", "unstructured": "Gordon AC, Mouncey PR, REMAP-CAP Investigators, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384 (16):1491–502.", "volume": "384", "year": "2021" }, { "DOI": "10.1016/j.antiviral.2018.03.003", "author": "L Delang", "doi-asserted-by": "publisher", "first-page": "85", "journal-title": "Antivir Res", "key": "496_CR7", "unstructured": "Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antivir Res. 2018;153:85–94.", "volume": "153", "year": "2018" }, { "DOI": "10.2183/pjab.93.027", "author": "Y Furuta", "doi-asserted-by": "publisher", "first-page": "449", "issue": "7", "journal-title": "Proc Jpn Acad Ser B Phys Biol Sci", "key": "496_CR8", "unstructured": "Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93 (7):449–63.", "volume": "93", "year": "2017" }, { "DOI": "10.1101/2020.03.17.20037432", "author": "C Chen", "doi-asserted-by": "publisher", "journal-title": "Infect Dis (except HIV/AIDS)", "key": "496_CR9", "unstructured": "Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial [Internet]. Infect Dis (except HIV/AIDS). 2020. https://doi.org/10.1101/2020.03.17.20037432.", "year": "2020" }, { "author": "ZF Udwadia", "first-page": "62", "journal-title": "Int J Infect Dis IJID Off Publ Int Soc Infect Dis", "key": "496_CR10", "unstructured": "Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021;103:62–71.", "volume": "103", "year": "2021" }, { "DOI": "10.1186/s13063-020-04825-x", "author": "M Bosaeed", "doi-asserted-by": "publisher", "first-page": "904", "issue": "1", "journal-title": "Trials", "key": "496_CR11", "unstructured": "Bosaeed M, Mahmoud E, Hussein M, et al. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21 (1):904.", "volume": "21", "year": "2020" }, { "DOI": "10.1056/NEJMoa2023184", "author": "H Pan", "doi-asserted-by": "publisher", "first-page": "497", "issue": "6", "journal-title": "N Engl J Med.", "key": "496_CR12", "unstructured": "Pan H, Peto R, WHO Solidarity Trial Consortium, et al. Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results. N Engl J Med. 2021;384 (6):497–511.", "volume": "384", "year": "2021" }, { "DOI": "10.1093/cid/ciaa237", "author": "X Yao", "doi-asserted-by": "publisher", "first-page": "732", "issue": "15", "journal-title": "Clin Infect Dis", "key": "496_CR13", "unstructured": "Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71 (15):732–9.", "volume": "71", "year": "2020" }, { "DOI": "10.1056/NEJMoa2007764", "author": "JH Beigel", "doi-asserted-by": "publisher", "first-page": "1813", "issue": "19", "journal-title": "N Engl J Med", "key": "496_CR14", "unstructured": "Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med. 2020;383 (19):1813–26.", "volume": "383", "year": "2020" }, { "DOI": "10.1001/jama.2020.16349", "author": "CD Spinner", "doi-asserted-by": "publisher", "first-page": "1048", "issue": "11", "journal-title": "JAMA", "key": "496_CR15", "unstructured": "Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324 (11):1048.", "volume": "324", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)31022-9", "author": "Y Wang", "doi-asserted-by": "publisher", "first-page": "1569", "issue": "10236", "journal-title": "Lancet Lond Engl", "key": "496_CR16", "unstructured": "Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Lond Engl. 2020;395 (10236):1569–78.", "volume": "395", "year": "2020" }, { "DOI": "10.1056/NEJMoa2016638", "author": "DR Boulware", "doi-asserted-by": "publisher", "first-page": "517", "issue": "6", "journal-title": "N Engl J Med", "key": "496_CR17", "unstructured": "Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;383 (6):517–25.", "volume": "383", "year": "2020" }, { "DOI": "10.1001/jama.2020.8630", "author": "ES Rosenberg", "doi-asserted-by": "publisher", "first-page": "2493", "issue": "24", "journal-title": "JAMA", "key": "496_CR18", "unstructured": "Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323 (24):2493–502.", "volume": "323", "year": "2020" }, { "DOI": "10.1056/NEJMoa2030340", "author": "C Salama", "doi-asserted-by": "publisher", "first-page": "20", "issue": "1", "journal-title": "N Engl J Med", "key": "496_CR19", "unstructured": "Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384 (1):20–30.", "volume": "384", "year": "2021" }, { "DOI": "10.1111/fcp.12586", "author": "F Lemaitre", "doi-asserted-by": "publisher", "first-page": "530", "issue": "5", "journal-title": "Fundam Clin Pharmacol", "key": "496_CR20", "unstructured": "Lemaitre F, Solas C, Grégoire M, et al. Potential drug–drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Fundam Clin Pharmacol. 2020;34 (5):530–47.", "volume": "34", "year": "2020" }, { "DOI": "10.1038/s41422-020-0282-0", "author": "M Wang", "doi-asserted-by": "publisher", "first-page": "269", "issue": "3", "journal-title": "Cell Res", "key": "496_CR21", "unstructured": "Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30 (3):269–71.", "volume": "30", "year": "2020" }, { "author": "B Singh", "first-page": "CD013587", "journal-title": "Cochrane Database Syst Rev.", "key": "496_CR22", "unstructured": "Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database Syst Rev. 2021;2:CD013587.", "volume": "2", "year": "2021" }, { "DOI": "10.1007/s00705-021-04956-9", "author": "HM Dabbous", "doi-asserted-by": "publisher", "first-page": "949", "issue": "3", "journal-title": "Arch Virol", "key": "496_CR23", "unstructured": "Dabbous HM, Abd-Elsalam S, El-Sayed MH, et al. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol. 2021;166 (3):949–54.", "volume": "166", "year": "2021" }, { "author": "AA Ivashchenko", "first-page": "1176", "journal-title": "Clin Infect Dis Off Publ Infect Dis Soc Am", "key": "496_CR24", "unstructured": "Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a Phase II/III multicenter randomized clinical trial. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020;2:1176.", "volume": "2", "year": "2020" }, { "DOI": "10.1016/j.intimp.2021.107522", "author": "M Solaymani-Dodaran", "doi-asserted-by": "publisher", "first-page": "107522", "journal-title": "Int Immunopharmacol.", "key": "496_CR25", "unstructured": "Solaymani-Dodaran M, Ghanei M, Bagheri M, et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol. 2021;95:107522.", "volume": "95", "year": "2021" }, { "DOI": "10.1056/NEJMoa2019014", "author": "AB Cavalcanti", "doi-asserted-by": "publisher", "first-page": "2041", "issue": "21", "journal-title": "N Engl J Med", "key": "496_CR26", "unstructured": "Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383 (21):2041–52.", "volume": "383", "year": "2020" }, { "DOI": "10.1128/AAC.01897-20", "author": "Y Doni", "doi-asserted-by": "crossref", "first-page": "e01897-20", "issue": "12", "journal-title": "Antimicrob Agents Chemother.", "key": "496_CR27", "unstructured": "Doni Y, Hibino M, Hase R, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020;64 (12):e01897-20.", "volume": "64", "year": "2020" } ], "reference-count": 27, "references-count": 27, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s40121-021-00496-6" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Infectious Diseases", "Microbiology (medical)" ], "subtitle": [], "title": "Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "10" }